About BiomarkerEDU

CE Symmetry, and CMEsolutions are excited to provide this innovative, educational resource focused on the evolving role of biomarker technology. Our long term mission with BiomarkerEDU.com is to provide a wide array of content, accredited and non-accredited, to help further the understanding and use of biomarker assays in the clinical, drug development and public health settings.

Biomarkers, defined in part by the World Health Organization as "any measurement reflecting an interaction between a biological system and a potential hazard, which may be chemical, physical, or biological. The measured response may be functional and physiological, biochemical at the cellular level, or a molecular interaction", have experienced a remarkable growth in the past 10 - 15 years. The role of biomarkers is anticipated to expand and will maintain a critical role in disease diagnosis and management, in clinical trial design and execution and will increasingly see a role in the public health sector.

We are now providing two substantial courses on the use of High-Sensitivity Troponin testing in the diagnosis of acute myocardial infarction. This new technology provides more precise diagnostic workup for the evaluation of chest pain in the ED. Our faculty discuss the role hs-Tn plays in the rule out of MI in the hospital.

“The High-Sensitivity Troponin Upgrade: It’s About Time” goes in depth into the rational for converting to high-sensitivity troponin testing. The expert faculty of Chris Baugh, Frank Peacock, Allan Jaffe, Brian Patel and Sayon Dutta all provide their thoughts and expertise on why hospitals should make this upgrade to their advanced diagnostic protocol (ADP) for MI diagnosis.

We also are providing a series on “how” to successfully adopt High-Sensitivity Troponin testing into the hospital’s advanced diagnostic protocol. Alan Wu joins Chris Baugh and Frank Peacock in presenting “Adoption of High-Sensitivity Troponin: A Step-by-Step Collaborative Guide” that is a discussion on the how-to setup a well-coordinated, well-resourced process to ensure a successful adoption of high-sensitivity troponin.

Our initial activity was a multi-faceted program launched in 2020 that focused on the use of procalcitonin in antimicrobial decision making. We were fortunate to be joined in this discussion by Dr. Jim Neuenschwander, Dr. Michael Broyles, and Dr. Eric Gluck. Their unique perspectives included laboratory, pharmacy, critical care, hospital, and emergency medicine. The panel reviewed the economics of procalcitonin and how it can improve practice behavior and improve patient outcomes.

Please complete the brief registration form and allow yourself the time to be educated and entertained as we take a tour of how procalcitonin can be used in the management of lower respiratory tract infections, COVID-19, predicting and treating sepsis, and antimicrobial stewardship.

As with many things beginning in 2020, COVID-19 had a significant impact on educational activities. The initial video content focused on the role of procalcitonin in directing patient management and antimicrobial therapy in the presence of COVID-19. We then added a high-definition video activity focusing on antimicrobial stewardship (AMS) and the role the procalcitonin biomarker assay can have in AMS efforts.

We are also offering a limited number of "live" events to institutions and chapters of appropriate medical societies. There will be no cost to the institution / chapter to host a live event. If you have an interest in having an event with your group, please email cme@biomarkeredu.com and we will reach out to you within 24 hours.

Thank you again for your interest.

We look forward to seeing your feedback.